Topical antibiotics limit depigmentation in a mouse model of vitiligo
Pigment Cell Melanoma Res. 2024 Mar 4. doi: 10.1111/pcmr.13164. Online ahead of print.ABSTRACTOral neomycin administration impacts the gut microbiome and delays vitiligo development in mice, and topical antibiotics may likewise allow the microbiome to preserve skin health and delay depigmentation. Here, we examined the effects of 6-week topical antibiotic treatment on vitiligo-prone pmel-1 mice. Bacitracin, Neosporin, or Vaseline were applied to one denuded flank, while the contralateral flank was treated with Vaseline in all mice. Ventral depigmentation was quantified weekly. We found that topical Neosporin treatment sign...
Source: Pigment Cell and Melanoma Research - March 5, 2024 Category: Cytology Authors: Ahmed Ahmed Touni Rachel Sohn Cormac Cosgrove Rohan S Shivde Emilia R Dellacecca Rasha T A Abdel-Aziz Kettil Cedercreutz Stefan J Green Hossam Abdel-Wahab I Caroline Le Poole Source Type: research
Novel Clinical Applications of Topical Ruxolitinib: A Case Series
J Drugs Dermatol. 2024 Mar 1;23(3):188-190. doi: 10.36849/jdd.7696.ABSTRACTTopical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatitis and vitiligo, recent reports suggest its potential efficacy in treating other dermatoses. Specifically, topical ruxolitinib may be an effective treatment option for refractory dermatological conditions that are inflammation-driven with dysregulated activity of cytokines implicated in the JAK/STAT pathway. In this case series, we present four novel clinical...
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Melissa P Zundell Roudha Al-Dehneem Teresa Song Jenna Yousif Alice B Gottlieb Source Type: research
